Premium
Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B‐cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE‐170 phase 2 trial
Author(s) -
Zinzani P.,
Thieblemont C.,
Melnichenko V.,
Osmanov D.,
Bouabdallah K.,
Walewski J.,
Majlis A.,
Fogliatto L.,
Caballero Barrigón M.D.,
Christian B.,
Gulbas Z.,
Özcan M.,
Salles G.A.,
Shipp M.A.,
Balakumaran A.,
Chlosta S.,
Chatterjee A.,
Armand P.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2437_49
Subject(s) - medicine , pembrolizumab , cohort , interim analysis , adverse effect , clinical endpoint , oncology , population , clinical trial , surgery , cancer , immunotherapy , environmental health